Skip to main content

Table 3 Comparison of efficacy for dabrafenib plus trametinib versus vemurafenib plus cobimetinib

From: Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients

Outcome COMBI-v coBRIM ITC results
D + T V V V + C HR/RRa LCI UCI p value
Overall survival, median (95% CI), months 25.6(22.6 − NR) 18.0(15.6 − 20.7) 17.4(15.0 − 19.8) 22.3(20.3 − NR) 0.94 0.68 1.30 0.7227
Progression-free survival, median (95% CI), months 12.6(10.7 − 15.5) 7.3(5.8 − 7.8) 7.2(5.6 – 7.5) 12.3(9.5 – 13.4) 1.05 0.79 1.40 0.7300
Overall response rate, no./total no. (%) 226/352(64%) 180/352(51%) 124/248(70%) 172/247(50%) 0.90 0.74 1.10 0.3029
  1. aFor D + T versus V + C; HR is the output for time-to-event outcomes, i.e., overall survival and progression-free survival; RR is the output for overall response rate
  2. CI confidence interval, D + T dabrafenib plus trametinib, HR hazard ratio, NR not reached, RR risk ratio, LCI lower 95% CI, UCI upper 95% CI, V vemurafenib, V + C vemurafenib plus cobimetinib